Paper392602
The mechanism of action of antitumor platinum compounds.
Roberts JJ and 1 other. Prog Nucleic Acid Res Mol Biol, 1979. Cited by 248 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The mechanism of action of antitumor platinum compounds. Papers, record 392602. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/392602
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| DNA, Neoplasm | Major topic |
| Platinum | Major topic |
| Animals | |
| Cisplatin | |
| DNA | |
| DNA Repair | |
| Escherichia coli | |
| Humans | |
| Ligands | |
| Mammals | |
| Structure-Activity Relationship |
Source PubMed
Cited by66
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 248 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42269607 | DNA repair drives cisplatin-induced neuronal death. | Cell | 2026 | https://conductscience.org/library/papers/42269607 | PubMed |
| 41273305 | Computational Analysis of a Next-Generation Platinum-Based Chemotherapies that Induce DNA Double-Strand Breaks. | J Chem Inf Model | 2026 | https://conductscience.org/library/papers/41273305 | PubMed |
| 40985211 | Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs. | Chem Rev | 2025 | https://conductscience.org/library/papers/40985211 | PubMed |
| 37071737 | Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications. | Chem Rev | 2023 | https://conductscience.org/library/papers/37071737 | PubMed |
| 35806229 | Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35806229 | PubMed |
| 35631926 | DNA Conformational Changes Induced by Its Interaction with Binuclear Platinum Complexes in Solution Indicate the Molecular Mechanism of Platinum Binding. | Polymers (Basel) | 2022 | https://conductscience.org/library/papers/35631926 | PubMed |
| 32354124 | Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy? | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32354124 | PubMed |
| 28724953 | Antimicrobial Efficacy and Synergy of Metal Ions against Enterococcus faecium, Klebsiella pneumoniae and Acinetobacter baumannii in Planktonic and Biofilm Phenotypes. | Sci Rep | 2017 | https://conductscience.org/library/papers/28724953 | PubMed |
| 23738524 | Monofunctional and higher-valent platinum anticancer agents. | Inorg Chem | 2013 | https://conductscience.org/library/papers/23738524 | PubMed |
| 22659329 | Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. | Pharmacol Rev | 2012 | https://conductscience.org/library/papers/22659329 | PubMed |
| 19259415 | The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells. | Cancer Inform | 2008 | https://conductscience.org/library/papers/19259415 | PubMed |
| 18231104 | Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. | Br J Cancer | 2008 | https://conductscience.org/library/papers/18231104 | PubMed |
| 17484128 | Chromatin as a target for the DNA-binding anticancer drugs. | Subcell Biochem | 2007 | https://conductscience.org/library/papers/17484128 | PubMed |
| 15840822 | RNA hydrolysis and inhibition of translation by a Co(III)-cyclen complex. | RNA | 2005 | https://conductscience.org/library/papers/15840822 | PubMed |
| 11856483 | Therapeutic and analysis model of intrahepatic metastasis reflects clinical behavior of hepatocellular carcinoma. | Jpn J Cancer Res | 2002 | https://conductscience.org/library/papers/11856483 | PubMed |
| 11477455 | Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma. | Cancer Gene Ther | 2001 | https://conductscience.org/library/papers/11477455 | PubMed |
| 9400943 | Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. | Br J Cancer | 1997 | https://conductscience.org/library/papers/9400943 | PubMed |
| 8609067 | Relationship between cell-killing efficiency and number of platinum atoms binding to DNA, RNA, and protein molecules in HeLa cells treated with cis-diamine(glycolato)platinum(II). | Jpn J Cancer Res | 1996 | https://conductscience.org/library/papers/8609067 | PubMed |
| 8286217 | The role of apoptosis in cell killing by cisplatin: a flow cytometric study. | Br J Cancer | 1994 | https://conductscience.org/library/papers/8286217 | PubMed |
| 8033299 | Effects of intralesional injection of cisplatin dissolved in urografin and lipiodol on Ehrlich ascites tumor and normal tissues of CD-1 mice. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8033299 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/392602
GET https://conductscience.org/api/papers/v1/392602/cited_by?page=2